{"id":"single-dose-iv-oritavancin-diphosphate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Infusion site reaction"}]},"_chembl":{"chemblId":"CHEMBL3989766","moleculeType":"Small molecule","molecularWeight":"1989.11"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oritavancin diphosphate binds to the cell wall precursor lipid II, preventing the incorporation of D-alanyl-D-alanine into the cell wall, ultimately leading to cell lysis and death. This mechanism of action is specific to Gram-positive bacteria, making it effective against a range of pathogens, including MRSA.","oneSentence":"Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:47.276Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"}]},"trialDetails":[{"nctId":"NCT02134301","phase":"PHASE1","title":"Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, LLC","startDate":"2014-05","conditions":"Gram-positive Bacterial Infections","enrollment":41},{"nctId":"NCT01762839","phase":"PHASE1","title":"A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2012-12-27","conditions":"Healthy","enrollment":150},{"nctId":"NCT01784536","phase":"PHASE1","title":"Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2013-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT02340988","phase":"PHASE1","title":"Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2015-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT01252719","phase":"PHASE3","title":"Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2010-12","conditions":"Wound Infection, Abscess, Systemic Inflammation","enrollment":968},{"nctId":"NCT01252732","phase":"PHASE3","title":"Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2010-12","conditions":"Wound Infection, Abscess, Systemic Inflammation","enrollment":1019},{"nctId":"NCT03873987","phase":"PHASE1","title":"Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2019-07-16","conditions":"Acute Bacterial Skin and Skin Structure Infection","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oritavancin Diphosphate"],"phase":"phase_3","status":"active","brandName":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","companyName":"Melinta Therapeutics, Inc.","companyId":"melinta-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria. Used for Acute bacterial skin and skin structure infections (ABSSSI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}